Veracyte Insider Sold Shares Worth $440,129, According to a Recent SEC Filing
A Veracyte insider recently sold 20,400 shares of the company's stock, valued at $440,129, according to an SEC filing. This transaction, occurring at an average price of $21.57 per share, was reported by the EVP and CFO of the company. Veracyte's stock (VCYT) has seen some volatility recently, with the company also reporting its latest quarterly earnings.
Veracyte director Robert S Epstein sells $440,129 in company stock
Robert S. Epstein, a director at Veracyte, Inc. (NASDAQ:VCYT), sold 10,000 shares of company stock totaling $440,129 on May 20, 2026, under a Rule 10b5-1 trading plan. The sale followed a 65% surge in the stock price over the past year, and despite the sale, Veracyte has shown strong financial results and expanded its product coverage.
Veracyte (VCYT) director sells 10,000-share block under 10b5-1 plan
Veracyte (VCYT) director Robert S. Epstein sold 10,000 shares of common stock at a weighted average price of $44.01 per share on May 20, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following the sale, Epstein directly owns 52,446 shares of Veracyte.
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
Veracyte, Inc. announced it will host an investor conference call and webcast on June 1, 2026, at 8:30 a.m. ET. The call will discuss data from two phase III clinical trials, OPTIMA and ENZAMET, using its Prosigna Breast and Decipher Prostate tests, which will be presented at the 2026 ASCO Annual Meeting. Professor Iain Macpherson, a principal investigator for OPTIMA, will join the discussion.
Kevin Haas Named Chief Development and Technology Officer at Veracyte
Veracyte Inc. has appointed Kevin Haas, Ph.D., as its new Chief Development and Technology Officer. In this newly created role, Dr. Haas will oversee the company's global product development strategy, focusing on diagnostic assay development, software, and bioinformatics. His extensive experience in life sciences and prior leadership positions at Myriad Genetics will be instrumental in advancing Veracyte's pipeline in multi-omics applications and delivering high-quality diagnostic solutions.
New cancer test data at ASCO aim to spare patients chemotherapy
Veracyte (NASDAQ: VCYT) announced that new data from two Phase III clinical trials, OPTIMA and ENZAMET, will be presented at the 2026 ASCO Annual Meeting. These trials demonstrate how Veracyte's Prosigna Breast and Decipher Prostate genomic tests can guide treatment decisions in breast and prostate cancer, potentially sparing patients from unnecessary chemotherapy and personalizing care. The findings aim to provide practice-changing evidence, helping clinicians optimize treatment intensity based on individual patient risk.
[144] VERACYTE, INC. SEC Filing
This article details a Form 144 SEC filing by Veracyte, Inc. (VCYT) dated May 20, 2026. The filing indicates a proposed sale of 10,000 shares of common stock with an aggregate market value of $416,900.00, acquired through previously exercised stock options on January 6, 2025.
Veracyte Jumps 7.8% Amid Sector-Wide Rally
Veracyte (VCYT) shares surged 7.8% to close at $44.96, primarily driven by a sector-wide rally in the diagnostics and research industry rather than company-specific news. Several peers also experienced significant gains, indicating broad investor interest in the healthcare innovation space. The rally, accompanied by increased trading volume, suggests a potential reassessment of the sector's risk-reward profile, though its sustainability remains to be seen without specific catalysts.
Why Veracyte (VCYT) Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test
Veracyte's TrueMRD Monitoring Test for bladder cancer recurrence has secured Medicare coverage, set to be commercially available on June 1, 2026. This Medicare backing is crucial for expanding its role in cancer care pathways, supporting its position as the only whole-genome MRD test available. Despite this positive development, the company still faces risks related to pricing pressure and revenue concentration, although a recent revenue guidance raise indicates management's confidence in test volumes.
Veracyte to Participate in Upcoming June 2026 Investor Conferences
Veracyte, Inc. announced its participation in two upcoming investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference. The company will deliver a presentation and a fireside chat, respectively, with live audio webcasts available on its investor relations website. Veracyte is a global diagnostics company focused on transforming cancer care through molecular tests and a robust Diagnostics Platform.
Veracyte stock (US92347M1009): diagnostics specialist back in the spotlight after new data and index
Veracyte (VCYT) has regained investor attention due to new clinical data for its Decipher Prostate genomic classifier and changes in its index inclusion. The company is strategically positioning its genomic tests for various cancers and lung diseases within the competitive precision medicine market, primarily generating revenue through testing services in its own laboratories, targeting US healthcare payers. Veracyte's performance is closely tied to US healthcare spending and its ability to demonstrate the clinical utility and cost-effectiveness of its genomic tests.
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. announced its participation in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference on June 2nd, and the Jefferies Global Healthcare Conference on June 4th. Live audio webcasts of these presentations will be available on Veracyte's website, with replays accessible for 90 days following each broadcast. The company specializes in molecular diagnostics for cancer care, utilizing genomic data, AI, and bioinformatics to help clinicians make informed decisions.
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Veracyte has announced that its TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC). This test, which utilizes a whole-genome sequencing approach, will be commercially launched on June 1, 2026, and aims to provide earlier detection of recurrence than traditional imaging methods, improving treatment decisions for MIBC patients. The company plans to expand its TrueMRD platform to other cancer types in the future.
A Look At Veracyte (VCYT) Valuation After Medicare Coverage For TrueMRD Cancer Monitoring Test
Veracyte (VCYT) has gained attention following Medicare coverage for its TrueMRD Monitoring Test, with commercial launch set for June 2026. While an analyst narrative suggests the stock is 18.1% undervalued with a fair value of $47.00 due to pipeline momentum, another perspective highlights a high P/E ratio of 34.9x compared to an industry average of 17.2x, indicating potential overvaluation or high market confidence. Investors are faced with assessing whether the Medicare win is sufficiently appreciated or if future growth is already factored into the current price.
Veracyte stock (US92347M1009): earnings momentum and cancer diagnostics focus
Veracyte, a genomic diagnostics company specializing in cancer testing, recently released its quarterly results and updated guidance, highlighting continued revenue growth and the costs associated with expanding its test portfolio. The company's focus remains on genomic tests for thyroid, lung, and other cancers, leveraging its central lab infrastructure and proprietary classifiers. Investors are keen to see how Veracyte balances growth with profitability in the competitive U.S. diagnostics market and navigates international expansion.
Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test
Veracyte has obtained Medicare coverage for its new bladder cancer monitoring test, which uses an AI-guided genomic platform to analyze urine samples for early, non-invasive detection of disease recurrence. This development is expected to significantly improve surveillance for patients who have undergone treatment for bladder cancer, potentially reducing the need for invasive procedures. The test, part of Veracyte's advanced diagnostic portfolio, aims to enhance patient care and clinical outcomes.
Veracyte (VCYT) Gains CMS Coverage for TrueMRD Monitoring Test
Veracyte Inc. (VCYT) announced that its TrueMRD Monitoring Test has received approval for coverage from the Centers for Medicare & Medicaid Services (CMS) for patients with muscle-invasive bladder cancer to monitor for recurrence. This approval, effective June 1, 2026, positions Veracyte as the sole provider of a comprehensive whole-genome MRD test commercially available, and despite insider selling, the company exhibits strong financial health and growth potential. The stock's current P/E ratio is 35.58x, suggesting investor expectations for future growth.
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test
Veracyte's TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC) following definitive treatment. This makes it Veracyte’s first molecular residual disease (MRD) commercial offering and the first commercially available whole-genome MRD test on the market. The test, which launches June 1, 2026, aims to improve early detection of recurrence and inform treatment decisions, especially as MIBC patients have a high recurrence rate within two years.
Veracyte’s bladder cancer test receives Medicare coverage
Veracyte's TrueMRD Monitoring Test for muscle-invasive bladder cancer has received Medicare coverage and will be commercially launched on June 1, 2026. This test helps monitor recurrence in patients after curative treatment, detecting it significantly earlier than imaging. The announcement follows strong financial performance by Veracyte and positive analyst revisions, despite the stock currently being considered slightly overvalued.
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Veracyte announced it has secured Medicare coverage for its TrueMRD Monitoring Test for patients with muscle-invasive bladder cancer (MIBC) from the CMS MolDX program. This marks the commercial launch of Veracyte’s first molecular residual disease (MRD) offering and the expansion of its cancer recurrence monitoring platform. The test, which will be available June 1, 2026, aims to provide earlier detection of recurrence than traditional imaging, thereby informing better treatment decisions for MIBC patients.
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings
Veracyte's stock has performed well due to strong earnings, despite unusual items reducing profit by US$12 million last year. These unusual expenses are considered one-off in nature, suggesting potential for higher profits next year if they don't recur. Analysts' forecasts indicate future profitability, underscoring the company's strong performance.
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings
Veracyte's recent stock performance aligns with its strong earnings, which were positively impacted by the one-off nature of unusual item deductions. Analysts expect improved profitability next year, as these unusual expenses are not anticipated to recur. The company's earnings per share have also shown impressive growth over the past year.
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors
Veracyte Inc (VCYT) shares dropped 3.3% to $38.26, making it slightly overvalued compared to its GF Value™ of $37.66. Despite this, the company holds a strong GF Score™ of 82/100, driven by excellent growth potential, although profitability remains a concern. Recent insider selling totaling $3.6 million suggests insidertakers might be taking profits and/or cautious about short-term prospects.
State of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYT
The State of New Jersey Common Pension Fund D has acquired a new position in Veracyte, Inc. (NASDAQ:VCYT), purchasing 26,852 shares valued at approximately $1.13 million in the fourth quarter. This investment follows Veracyte's strong financial performance, reporting EPS of $0.52 against an expected $0.34 and a 21.5% year-over-year revenue increase to $139.07 million. Despite insider share sales from individuals like CEO Marc Stapley, the stock holds a "Hold" rating from analysts with an average target price of $44.83.
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte
State Street Corporation has disclosed a beneficial ownership of 5,043,590 shares in Veracyte Inc. (VCYT), representing 6.3% of the company's common stock as of March 31, 2026. This Schedule 13G filing indicates a passive investment, with various State Street advisory subsidiaries holding shared voting and dispositive powers over the shares. The disclosure is routine for institutional investors crossing the 5% ownership threshold.
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies
Veracyte (VCYT) shares rose 23.8% after the company reported strong Q1 2026 results with revenue up to US$139.07 million and net income at US$28.71 million, exceeding analyst expectations. The company also raised its full-year 2026 revenue guidance to US$582 million–US$592 million and expanded its Decipher cancer studies, reinforcing its leadership in genomic testing for personalized cancer care. Despite these positive updates, investors are cautioned to consider potential pricing and reimbursement pressures.
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies
Veracyte (VCYT) reported strong first-quarter 2026 results, with revenue and net income exceeding expectations, leading to a 23.8% stock increase and an upgraded full-year 2026 revenue guidance to US$582 million–US$592 million. The company is also expanding the clinical application of its Decipher portfolio, presenting over 15 new cancer studies. This financial strength and clinical expansion reinforce Veracyte's investment narrative, although product concentration remains a key risk.
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT)
Annie Mcguire, Senior Vice President and General Counsel at Veracyte Inc (VCYT), sold 10,204 shares of the company on May 6, 2026. This transaction is part of a broader trend of insider selling at Veracyte, with 29 insider sells and no buys over the past year. The stock was trading at $39.03 at the time of sale and is considered fairly valued according to its GF Value.
Veracyte SVP McGuire sells $398,211 in shares
Annie McGuire, SVP and General Counsel at Veracyte, Inc. (NASDAQ: VCYT), sold 10,204 shares of the company's common stock for $398,211 on May 6, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted in August 2025. The transaction follows recent strong performance for Veracyte's stock and impressive first-quarter earnings for 2026, exceeding analyst expectations for both EPS and revenue.
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan
Veracyte's Senior Vice President and General Counsel, Annie McGuire, sold 10,204 shares of common stock in open-market transactions on May 6, 2026, at prices of $40.00 and $38.05 per share. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on August 29, 2025. Following these transactions, McGuire directly owns 143,708 shares of Veracyte common stock.
Number of shareholders of Veracyte, Inc. – MUN:12V
This article from TradingView provides a financial overview of Veracyte, Inc. (MUN:12V) on the Munich Stock Exchange. It focuses on the number of shareholders, displaying period, value, and change metrics. The content itself seems to be a template or placeholder, as it doesn't contain actual shareholder data but rather the structure for it.
Veracyte (Nasdaq:VCYT) - Stock Analysis
This Simply Wall St analysis covers Veracyte (VCYT), highlighting its stock performance, financial health, and future growth prospects. The company is trading 24.9% below its fair value, with earnings forecast to grow by 8.2% annually. Recent updates include increased earnings guidance for 2026, strong Q1 2026 results driven by testing revenue, and new data presentations on its Decipher and Afirma portfolios, underscoring its focus on growth in cancer diagnostics.
Veracyte, Inc. 1Q 2026: Revenue $139.07M, EPS $0.35— 10-Q Summary
Veracyte, Inc. reported strong first-quarter 2026 results with revenue of $139.07 million and diluted EPS of $0.35, representing significant year-over-year growth due to increased test volumes and higher pricing. The company's revenue growth was primarily driven by a 26% increase in testing revenue, with strong demand for existing products and preparations for new launches. Veracyte also achieved profitability for the quarter and increased its cash position to support future R&D and lab scaling initiatives.
Veracyte (NASDAQ: VCYT) Q1 profit surges as revenue climbs 21%
Veracyte (NASDAQ: VCYT) reported a strong first quarter of 2026, with total revenue increasing by 21% year-over-year to $139.1 million, primarily driven by a 26% rise in testing revenue. The company's net income quadrupled to $28.7 million, with diluted EPS growing to $0.35, reflecting improved operating leverage and increased diagnostic test volumes. Veracyte also maintained a strong cash position of $439.1 million in cash, cash equivalents, and short-term investments, supporting ongoing investments in R&D and new cancer diagnostic offerings like the TrueMRD platform.
VCYT Stock Jumps As Raised Guidance Fuels Bullish Momentum
Veracyte Inc. (VCYT) stock surged by 22.25% after announcing strong Q1 2026 results, including a 21% revenue increase and quadrupled GAAP net income. The company also raised its full-year 2026 revenue guidance to $582M–$592M and adjusted EBITDA margin target, signaling increased confidence. Analysts like Jefferies initiated coverage with a Buy rating and a $45 price target, driven by robust diagnostics growth and a promising pipeline.
FMR LLC (NASDAQ: VCYT) discloses 9.7% holding — 7.7M shares
FMR LLC has filed an amendment to its Schedule 13G/A, disclosing a 9.7% beneficial ownership in Veracyte Inc. (NASDAQ: VCYT), which amounts to 7,703,848.74 shares of common stock. This filing, also involving Abigail P. Johnson, indicates a passive investment with sole dispositive power over these shares, rather than an active acquisition intent. The document outlines key figures such as beneficial ownership, percentage of class, and sole voting and dispositive powers.
Veracyte Surges 21.1% Amid Sector-Wide Rally
Veracyte (VCYT) shares surged 21.1% to $39.92 on Wednesday with elevated trading volume, as the diagnostics and research sector experienced a broad rally. While other sector peers also saw gains, Veracyte's significant outperformance suggests additional factors or investor attention beyond the general sector tailwind. The rally increased the company's market capitalization to $3.2 billion, but without specific company news, the move is attributed to sector-wide buying interest.
Veracyte Surges 21.1% Amid Sector-Wide Rally
Veracyte (VCYT) shares surged 21.1% on Wednesday, reaching $39.92, as part of a broad rally that swept through the diagnostics and research sector. Although several peer companies also saw gains, Veracyte's outperformance suggests additional factors or disproportionate investor interest in genomic testing drove its significant increase. Investors are advised to monitor if these gains are sustained and look for company-specific news or continued sector rotation.
UBS Adjusts Price Target on Veracyte to $52 From $48, Maintains Buy Rating
UBS has increased its price target for Veracyte (VCYT) to $52 from $48, while reaffirming a Buy rating on the stock. This adjustment follows Veracyte's recent financial performance, including a rise in Q1 non-GAAP earnings and revenue, and an upward revision of its 2026 revenue guidance. The company's shares reacted positively to this news, trading higher pre-bell.
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT) reported strong Q1 2026 results, exceeding revenue and profitability expectations, driven by double-digit growth in its Decipher and Afirma tests. The company is preparing for two major product launches: Prosigna LDT for breast cancer and TruMRD for minimal residual disease, initially focusing on muscle-invasive bladder cancer. Veracyte raised its full-year 2026 revenue guidance to $582 million to $592 million and adjusted EBITDA guidance to greater than 26%, reflecting continued investment in growth initiatives.
Veracyte Announces First Quarter 2026 Financial Results
Veracyte Inc. announced strong financial results for the first quarter of 2026, with total revenue increasing by 21% to $139.1 million and testing revenue rising by 26% to $135.1 million, exceeding profitability targets. The company reported GAAP net income of $28.7 million and adjusted EBITDA of $42.8 million. Veracyte is raising its full-year 2026 revenue guidance to $582 million to $592 million and expects significant growth from upcoming product launches like Prosigna LDT and TrueMRD.
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates
Veracyte (VCYT) reported strong Q1 earnings of $0.52 per share, significantly surpassing the Zacks Consensus Estimate of $0.34, and also exceeded revenue estimates with $139.07 million. Despite the positive financial results, the company's shares have underperformed the S&P 500 year-to-date, leading to investor questions about its future stock performance. The current Zacks Rank #2 (Buy) suggests an expected outperformance in the near term, with favorable earnings estimate revisions prior to this report.
Veracyte (VCYT) Q1 2026 Earnings Transcript
Veracyte (VCYT) reported strong financial results for Q1 2026, with total revenue reaching $139.1 million, a 21% year-over-year increase, driven by Decipher and Afirma test growth. The company raised its full-year 2026 revenue guidance to $582 million to $592 million and increased its adjusted EBITDA guidance to greater than 26% of revenue. Veracyte is also preparing for the commercial launches of Prosigna LDT and TruMRD, which are expected to be significant growth catalysts.
Veracyte: Q1 Earnings Snapshot
Veracyte Inc. reported strong first-quarter earnings, exceeding Wall Street expectations with net income of $28.7 million, or 52 cents per share adjusted. The molecular diagnostic company also surpassed revenue forecasts, posting $139.1 million, and projects full-year revenue between $582 million and $592 million.
Veracyte (NASDAQ: VCYT) boosts Q1 profit and raises 2026 outlook
Veracyte (NASDAQ: VCYT) announced strong first-quarter 2026 financial results, with total revenue increasing 21% to $139.1 million and GAAP net income reaching $28.7 million. The growth was primarily driven by its Decipher and Afirma cancer diagnostic tests. The company also raised its full-year 2026 revenue and adjusted EBITDA margin outlook, reflecting confidence in its growth trajectory and upcoming product launches.
Veracyte earnings loom: Investors watch for TrueMRD launch details By Investing.com
Veracyte Inc. is reporting first-quarter earnings, with analysts anticipating earnings of 33 cents per share and revenue of $130.2 million. Investors are keenly focused on the company's ability to maintain profitable growth and the upcoming launch of its TrueMRD minimal residual disease platform. Key areas of investor scrutiny include the robustness of its core diagnostic products, details on the TrueMRD commercial launch, and the company's profitability trends amidst new product development and rollout.
Vanguard reports 5.2% stake in Veracyte (VCYT) via Schedule 13G
Vanguard Capital Management has reported a 5.2% beneficial ownership stake in Veracyte Inc. (VCYT) through a Schedule 13G filing. As of March 31, 2026, Vanguard beneficially owns 4,132,224 shares, with sole dispositive power over all these shares and sole voting power over 599,992 shares. The filing indicates the shares are held for investment purposes and not to influence control.
Will New Decipher Evidence at AUA 2026 Shift Veracyte's (VCYT) Precision Oncology Narrative?
Veracyte recently announced that over 15 studies on its Decipher prostate and bladder cancer diagnostics were presented at the 2026 American Urological Association Annual Meeting, highlighting their role in personalized urologic cancer care. This expanded clinical evidence base supports near-term adoption, though the biggest risk remains concentrated reliance on a few core assays in a competitive market. Investors should also be aware of rising reimbursement scrutiny that could pressure pricing and margins over time, despite promising revenue and earnings forecasts.
Vanguard Portfolio Management (VCYT) reports 4.51M shares, 5.67% stake
Vanguard Portfolio Management LLC has reported a beneficial ownership of 4,512,852 shares of Veracyte Inc. common stock, which represents a 5.67% stake in the company. The filing, a Schedule 13G, indicates that Vanguard holds sole voting power over 68,122 shares and sole dispositive power over all 4,512,852 shares. This disclosure, signed by Ashley Grim on April 29, 2026, details Vanguard's investment purposes rather than control objectives.
Veracyte (VCYT) to Release Earnings on Tuesday
Veracyte (VCYT) is scheduled to release its Q1 2026 earnings after market close on Tuesday, May 5th, with analysts expecting $0.34 EPS and $130.14 million in revenue. The company beat estimates in the prior quarter and analysts project $1 EPS for the current and next fiscal year. Shares traded around $33.12, and insiders, including the CEO and CFO, recently sold a significant amount of stock.
